HSIC250117P50000
- 0.20
- 0.000.00%
Henry Schein Newsroom
Henry Schein Raised to Buy From Underperform by B of A Securities
Henry Schein Analyst Ratings
BofA Securities Upgrades Henry Schein(HSIC.US) to Buy Rating, Announces Target Price $84
Analysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Henry Schein (HSIC) and Geron (GERN)
Henry Schein Analyst Ratings
Mizuho Initiates Coverage On Henry Schein With Neutral Rating, Announces Price Target of $75
Hold Rating Maintained for Henry Schein Amid Market Challenges and Activist Investor Influence
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $83
Piper Sandler Keeps Their Buy Rating on Henry Schein (HSIC)
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $74 to $83
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
Henry Schein Is Maintained at Outperform by Barrington Research
Henry Schein Price Target Maintained With a $82.00/Share by Barrington Research
Henry Schein Analyst Ratings
Henry Schein: Buy Rating Affirmed Amid Strong Profitability and Strategic Cost Management
A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $55 to $83
Henry Schein (HSIC) Gets a Buy From Piper Sandler
Henry Schein's Sell Rating: Internal Sales Weakness and Valuation Concerns Amidst Cybersecurity and Market Challenges
Evercore ISI Sticks to Their Hold Rating for Henry Schein (HSIC)
BofA Securities Maintains Henry Schein(HSIC.US) With Sell Rating